First Header Logo Second Header Logo

Connection

Peter Clark to Humans

Back to Details
This is a "connection" page, showing publications Peter Clark has written about Humans.
Peter Clark
Connection Strength
2.239
Humans
  1. Balci M, Glaser ZA, Chang SS, Herrell SD, Barocas DA, Keegan KA, Moses KA, Resnick MJ, Smith JA, Penson DF, Scarpato K, Clark PE. Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma. J Cancer Res Ther. 2021 Apr-Jun; 17(2):420-425.
    View in: PubMed
    Score: 0.044
  2. Raghavan D, Tan AR, Story ES, Burgess EF, Musselwhite L, Kim ES, Clark PE. Management changes for patients with endocrine-related cancers in the COVID-19 pandemic. Endocr Relat Cancer. 2020 09; 27(9):R357-R374.
    View in: PubMed
    Score: 0.043
  3. Clark PE. Editorial Comment. J Urol. 2018 05; 199(5):1317-1318.
    View in: PubMed
    Score: 0.036
  4. Polosukhina D, Love HD, Moses HL, Lee E, Zent R, Clark PE. Pharmacologic Inhibition of ß-Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor. Oncol Res. 2017 Nov 02; 25(9):1653-1664.
    View in: PubMed
    Score: 0.034
  5. Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol. 2017 04; 11(4):405-421.
    View in: PubMed
    Score: 0.034
  6. Glaser ZA, Love HD, Guo S, Gellert L, Chang SS, Herrell SD, Barocas DA, Penson DF, Cookson MS, Clark PE. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. Urol Oncol. 2017 05; 35(5):286-293.
    View in: PubMed
    Score: 0.033
  7. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 10; 14(10):1213-1224.
    View in: PubMed
    Score: 0.032
  8. Fowke JH, Koyama T, Fadare O, Clark PE. Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms. PLoS One. 2016; 11(6):e0156918.
    View in: PubMed
    Score: 0.032
  9. Scarpato KR, Tyson MD, Clark PE. Natural biology and management of nonmuscle invasive bladder cancer. Curr Opin Oncol. 2016 May; 28(3):210-5.
    View in: PubMed
    Score: 0.032
  10. Clark PE. Toward Personalized Guidelines in Bladder Cancer. J Natl Compr Canc Netw. 2015 Dec; 13(12):1458-60.
    View in: PubMed
    Score: 0.031
  11. Clark PE. Urothelial carcinoma with squamous differentiation: response to chemotherapy and radiation. Urol Oncol. 2015 Oct; 33(10):434-6.
    View in: PubMed
    Score: 0.030
  12. Lipworth L, Morgans AK, Edwards TL, Barocas DA, Chang SS, Herrell SD, Penson DF, Resnick MJ, Smith JA, Clark PE. Renal cell cancer histological subtype distribution differs by race and sex. BJU Int. 2016 Feb; 117(2):260-5.
    View in: PubMed
    Score: 0.030
  13. Eifler JB, Scarpato KR, Clark PE. Management of noninvasive bladder cancers. Curr Opin Oncol. 2015 May; 27(3):185-90.
    View in: PubMed
    Score: 0.029
  14. Kaffenberger SD, Lin-Tsai O, Stratton KL, Morgan TM, Barocas DA, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol. 2015 Jan; 33(1):21.e11-21.e17.
    View in: PubMed
    Score: 0.028
  15. Bassett JC, Eifler JB, Resnick MJ, Clark PE. Developments and controversies in the management of noninvasive bladder cancer. Curr Opin Oncol. 2014 May; 26(3):299-304.
    View in: PubMed
    Score: 0.027
  16. Clark PE. T1 high-grade bladder cancer recurring after BCG therapy: radical cystectomy is still the best approach. Pro. Oncology (Williston Park). 2013 Sep; 27(9):872, 921.
    View in: PubMed
    Score: 0.026
  17. Resnick MJ, Bassett JC, Clark PE. Management of superficial and muscle-invasive urothelial cancers of the bladder. Curr Opin Oncol. 2013 May; 25(3):281-8.
    View in: PubMed
    Score: 0.026
  18. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013 May 01; 11(5):594-615.
    View in: PubMed
    Score: 0.026
  19. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Netw. 2013 Apr 01; 11(4):446-75.
    View in: PubMed
    Score: 0.025
  20. Morgan TM, Seeley EH, Fadare O, Caprioli RM, Clark PE. Imaging the clear cell renal cell carcinoma proteome. J Urol. 2013 Mar; 189(3):1097-103.
    View in: PubMed
    Score: 0.025
  21. Kaffenberger SD, Morgan TM, Stratton KL, Boachie AM, Barocas DA, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. BJU Int. 2012 Dec; 110(11 Pt B):E641-6.
    View in: PubMed
    Score: 0.025
  22. Fowke JH, Phillips S, Koyama T, Byerly S, Concepcion R, Motley SS, Clark PE. Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. BJU Int. 2013 Jan; 111(1):122-8.
    View in: PubMed
    Score: 0.024
  23. Keegan KA, Resnick MJ, Clark PE. Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder. Curr Opin Oncol. 2012 May; 24(3):278-83.
    View in: PubMed
    Score: 0.024
  24. Clark PE, Polosukhina D, Love H, Correa H, Coffin C, Perlman EJ, de Caestecker M, Moses HL, Zent R. ß-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors. Am J Pathol. 2011 Dec; 179(6):3045-55.
    View in: PubMed
    Score: 0.023
  25. Morgan TM, Keegan KA, Clark PE. Bladder cancer. Curr Opin Oncol. 2011 May; 23(3):275-82.
    View in: PubMed
    Score: 0.022
  26. Morgan TM, Tang D, Stratton KL, Barocas DA, Anderson CB, Gregg JR, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol. 2011 Jun; 59(6):923-8.
    View in: PubMed
    Score: 0.022
  27. DeGraff DJ, Clark PE. Detection of tumor cells in the bone offers independent prognostic value in bladder cancer patients: the clinical and basic science perspective. Eur Urol. 2011 Aug; 60(2):239-40.
    View in: PubMed
    Score: 0.022
  28. Clark PE, Polosukhina DA, Gyabaah K, Moses HL, Thorburn A, Zent R. TRAIL and interferon-alpha act synergistically to induce renal cell carcinoma apoptosis. J Urol. 2010 Sep; 184(3):1166-74.
    View in: PubMed
    Score: 0.021
  29. Morgan TM, Clark PE. Bladder cancer. Curr Opin Oncol. 2010 May; 22(3):242-9.
    View in: PubMed
    Score: 0.021
  30. Clark PE. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 2009 Nov; 76(9):939-45.
    View in: PubMed
    Score: 0.020
  31. Clark PE. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2009 Jun; 9(6):821-30.
    View in: PubMed
    Score: 0.020
  32. Bischoff CJ, Clark PE. Bladder cancer. Curr Opin Oncol. 2009 May; 21(3):272-7.
    View in: PubMed
    Score: 0.019
  33. Boudreaux KJ, Chang SS, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Clark PE. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer. 2009 Feb 15; 115(4):770-5.
    View in: PubMed
    Score: 0.019
  34. Clark PE. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. Eur Urol. 2009 Jun; 55(6):1343-4.
    View in: PubMed
    Score: 0.019
  35. Coons BJ, Stec AA, Stratton KL, Chang SS, Cookson MS, Duke Herrell S, Smith JA, Clark PE. Prognostic factors in T3b renal cell carcinoma. World J Urol. 2009 Feb; 27(1):75-9.
    View in: PubMed
    Score: 0.019
  36. Clark PE, Cookson MS. The von Hippel-Lindau gene: turning discovery into therapy. Cancer. 2008 Oct 01; 113(7 Suppl):1768-78.
    View in: PubMed
    Score: 0.019
  37. Koski ME, Tedesco JM, Clark PE. Renal peripheral neuroectodermal tumor presenting at age 78: case report. ScientificWorldJournal. 2008 Aug 31; 8:830-4.
    View in: PubMed
    Score: 0.019
  38. Barocas DA, Clark PE. Bladder cancer. Curr Opin Oncol. 2008 May; 20(3):307-14.
    View in: PubMed
    Score: 0.018
  39. Stec AA, Coons BJ, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE. Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma--does it affect survival? J Urol. 2008 Jun; 179(6):2152-7.
    View in: PubMed
    Score: 0.018
  40. Clark PE. Upper tract transitional cell carcinoma: finding a way forward. Cancer. 2007 Oct 15; 110(8):1648-9.
    View in: PubMed
    Score: 0.017
  41. Clark PE. Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol. 2007 Sep; 17(5):331-6.
    View in: PubMed
    Score: 0.017
  42. Zagoria RJ, Traver MA, Werle DM, Perini M, Hayasaka S, Clark PE. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol. 2007 Aug; 189(2):429-36.
    View in: PubMed
    Score: 0.017
  43. Heilbrun ME, Zagoria RJ, Garvin AJ, Hall MC, Krehbiel K, Southwick A, Clark PE. CT-guided biopsy for the diagnosis of renal tumors before treatment with percutaneous ablation. AJR Am J Roentgenol. 2007 Jun; 188(6):1500-5.
    View in: PubMed
    Score: 0.017
  44. Clark PE. Bladder cancer. Curr Opin Oncol. 2007 May; 19(3):241-7.
    View in: PubMed
    Score: 0.017
  45. Clark PE, Woodruff RD, Zagoria RJ, Hall MC. Microwave ablation of renal parenchymal tumors before nephrectomy: phase I study. AJR Am J Roentgenol. 2007 May; 188(5):1212-4.
    View in: PubMed
    Score: 0.017
  46. Phillips JJ, Hall MC, Lee WR, Clark PE. Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? Urol Oncol. 2007 May-Jun; 25(3):196-200.
    View in: PubMed
    Score: 0.017
  47. Clark PE, Hall MC, Borden LS, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R, Lovato J, Harmon M, Torti FM. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology. 2006 Jun; 67(6):1257-61.
    View in: PubMed
    Score: 0.016
  48. Gwynn ES, Clark PE. Bladder cancer. Curr Opin Oncol. 2006 May; 18(3):277-83.
    View in: PubMed
    Score: 0.016
  49. Gwynn ES, Clark PE. Inflammatory myofibroblastic tumor associated with renal cell carcinoma. Urology. 2005 Oct; 66(4):880.
    View in: PubMed
    Score: 0.015
  50. Clark PE, Veys JA, Eskridge MR, Woodruff RD, Hall MC. Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era. Urol Oncol. 2005 Sep-Oct; 23(5):328-32.
    View in: PubMed
    Score: 0.015
  51. Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer. 2005 Jul 01; 104(1):36-43.
    View in: PubMed
    Score: 0.015
  52. Clark PE, Hall MC. Contemporary management of the urethra in patients after radical cystectomy for bladder cancer. Urol Clin North Am. 2005 May; 32(2):199-206.
    View in: PubMed
    Score: 0.015
  53. Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG. Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer. 2005 Feb 01; 103(3):546-52.
    View in: PubMed
    Score: 0.014
  54. Clark PE, Farver CF, Ulchaker JC, Angermeier K. A rare case of an extra-adrenal myelolipoma arising in the renal sinus: a case report and review of the literature. ScientificWorldJournal. 2005 Jan 28; 5:109-17.
    View in: PubMed
    Score: 0.014
  55. Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol. 2004 Oct; 172(4 Pt 1):1342-7.
    View in: PubMed
    Score: 0.014
  56. Clark PE, Streem SB. Endourologic management of upper tract transitional cell carcinoma. ScientificWorldJournal. 2004 Jun 07; 4 Suppl 1:62-75.
    View in: PubMed
    Score: 0.014
  57. Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology. 2004 Jun; 63(6):1061-5.
    View in: PubMed
    Score: 0.014
  58. Clark PE, Torti FM. Prostate cancer and bone metastases: medical treatment. Clin Orthop Relat Res. 2003 Oct; (415 Suppl):S148-57.
    View in: PubMed
    Score: 0.013
  59. Clark PE, Irvine RA, Coetzee GA. The androgen receptor CAG repeat and prostate cancer risk. Methods Mol Med. 2003; 81:255-66.
    View in: PubMed
    Score: 0.013
  60. Clark PE. Urinary diversion after radical cystectomy. Curr Treat Options Oncol. 2002 Oct; 3(5):389-402.
    View in: PubMed
    Score: 0.012
  61. Darst BF, Hughley R, Pfennig A, Hazra U, Fan C, Wan P, Sheng X, Xia L, Andrews C, Chen F, Berndt SI, Kote-Jarai Z, Govindasami K, Bensen JT, Ingles SA, Rybicki BA, Nemesure B, John EM, Fowke JH, Huff CD, Strom SS, Isaacs WB, Park JY, Zheng W, Ostrander EA, Walsh PC, Carpten J, Sellers TA, Yamoah K, Murphy AB, Sanderson M, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Kittles RA, Xu J, Stern MC, Chokkalingam AP, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Kibel AS, Klein EA, Goodman PJ, Stanford JL, Drake BF, Hu JJ, Clark PE, Blanchet P, Casey G, Hennis AJM, Lubwama A, Thompson IM, Leach RJ, Gundell SM, Pooler L, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Brureau L, Blot WJ, Biritwum R, Tay E, Truelove A, Niwa S, Tettey Y, Varma R, McKean-Cowdin R, Torres M, Jalloh M, Magueye Gueye S, Niang L, Ogunbiyi O, Oladimeji Idowu M, Popoola O, Adebiyi AO, Aisuodionoe-Shadrach OI, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Yeboah ED, Mensah JE, Anthony Adjei A, Diop H, Cook MB, Chanock SJ, Watya S, Eeles RA, Chiang CWK, Lachance J, Rebbeck TR, Conti DV, Haiman CA. A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. Eur Urol. 2022 May; 81(5):458-462.
    View in: PubMed
    Score: 0.012
  62. Campbell SC, Uzzo RG, Karam JA, Chang SS, Clark PE, Souter L. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. J Urol. 2021 Aug; 206(2):209-218.
    View in: PubMed
    Score: 0.011
  63. Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol. 2021 Aug; 206(2):199-208.
    View in: PubMed
    Score: 0.011
  64. Lu CD, Adeyemi O, Anderson WE, Hetherington TC, Slawson DC, Tapp H, Eaton TA, Burgess EF, Grigg CM, Zhu JZ, Gaston KE, Riggs SB, Clark PE, Taylor YJ, Kearns JT. Racial Disparities in Prostate Specific Antigen Screening and Referral to Urology in a Large, Integrated Health Care System: A Retrospective Cohort Study. J Urol. 2021 08; 206(2):270-278.
    View in: PubMed
    Score: 0.011
  65. Fonseca RB, Straub Hogan MM, Kapp ME, Cate F, Coogan A, Arora S, Gordetsky J, Smelser WW, Clark PE, Cates J, Giannico GA. Diagnostic renal mass biopsy is associated with individual categories of PADUA and RENAL nephrometry scores: Analysis of diagnostic and concordance rates with surgical resection. Urol Oncol. 2021 06; 39(6):371.e7-371.e15.
    View in: PubMed
    Score: 0.011
  66. Kumar B, Ahmad R, Giannico GA, Zent R, Talmon GA, Harris RC, Clark PE, Lokeshwar V, Dhawan P, Singh AB. Claudin-2 inhibits renal clear cell carcinoma progression by inhibiting YAP-activation. J Exp Clin Cancer Res. 2021 Feb 23; 40(1):77.
    View in: PubMed
    Score: 0.011
  67. Clark PE, Novick AC. Exophytic noninvasive growth pattern of renal angiomyolipomas: implications for nephron sparing surgery. J Urol. 2001 Feb; 165(2):513-4.
    View in: PubMed
    Score: 0.011
  68. Clark PE, Schover LR, Uzzo RG, Hafez KS, Rybicki LA, Novick AC. Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue. Urology. 2001 Feb; 57(2):252-6.
    View in: PubMed
    Score: 0.011
  69. Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 2001 Feb; 57(2):281-5.
    View in: PubMed
    Score: 0.011
  70. Patel SR, Futral C, Miller CA, Bose R, Kearns J, Clark PE, Roy OP. Demographic and Socioeconomic Factors Associated with Urinary Stone Disease Management in a Large Urban US Population. Urology. 2021 07; 153:93-100.
    View in: PubMed
    Score: 0.011
  71. Kohrt SE, Awadallah WN, Phillips RA, Case TC, Jin R, Nanda JS, Yu X, Clark PE, Yi Y, Matusik RJ, Anderson PD, Grabowska MM. Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells In Vitro. Mol Cancer Ther. 2021 02; 20(2):398-409.
    View in: PubMed
    Score: 0.011
  72. Grigg CM, Livasy C, He J, Hartman A, Clark PE, Zhu J, Raghavan D, Burgess EF. Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity. Hum Pathol. 2021 01; 107:96-103.
    View in: PubMed
    Score: 0.011
  73. Nanda JS, Awadallah WN, Kohrt SE, Popovics P, Cates JMM, Mirosevich J, Clark PE, Giannico GA, Grabowska MM. Increased nuclear factor I/B expression in prostate cancer correlates with AR expression. Prostate. 2020 09; 80(13):1058-1070.
    View in: PubMed
    Score: 0.011
  74. Townsend WB, Worrilow WM, Robinson MM, Beano H, Parker B, Gaston KE, Clark PE, Riggs SB. Implementation of a Dedicated Enhanced Recovery after Surgery (ERAS) Program for Radical Cystectomy Patients is Associated With Decreased Postoperative Inpatient Opioid Usage and Pain Scores. Urology. 2020 09; 143:186-193.
    View in: PubMed
    Score: 0.010
  75. Darst BF, Wan P, Sheng X, Bensen JT, Ingles SA, Rybicki BA, Nemesure B, John EM, Fowke JH, Stevens VL, Berndt SI, Huff CD, Strom SS, Park JY, Zheng W, Ostrander EA, Walsh PC, Srivastava S, Carpten J, Sellers TA, Yamoah K, Murphy AB, Sanderson M, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Yeager M, Petrovics G, Cullen J, Neslund-Dudas C, Kittles RA, Xu J, Stern MC, Kote-Jarai Z, Govindasami K, Chokkalingam AP, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Kibel AS, Klein EA, Goodman PJ, Drake BF, Hu JJ, Clark PE, Blanchet P, Casey G, Hennis AJM, Lubwama A, Thompson IM, Leach R, Gundell SM, Pooler L, Xia L, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Eeles RA, Brureau L, Chanock SJ, Watya S, Stanford JL, Mandal D, Isaacs WB, Cooney K, Blot WJ, Conti DV, Haiman CA. A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. Eur Urol. 2020 09; 78(3):316-320.
    View in: PubMed
    Score: 0.010
  76. Beano H, He J, Hensel C, Worrilow W, Townsend W, Gaston K, Clark PE, Riggs S. Safety of decreasing ureteral stent duration following radical cystectomy. World J Urol. 2021 Feb; 39(2):473-479.
    View in: PubMed
    Score: 0.010
  77. Burgess EF, Livasy C, Trufan S, Hartman A, Guerreri R, Naso C, Clark PE, Grigg C, Symanowski J, Raghavan D. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy. Urol Oncol. 2019 12; 37(12):900-906.
    View in: PubMed
    Score: 0.010
  78. Clark PE, Klein EA. Surgery for invasive bladder tumors: technique and outcome. Curr Opin Urol. 1999 Sep; 9(5):413-8.
    View in: PubMed
    Score: 0.010
  79. Laskar RS, Muller DC, Li P, Machiela MJ, Ye Y, Gaborieau V, Foll M, Hofmann JN, Colli L, Sampson JN, Wang Z, Bacq-Daian D, Boland A, Abedi-Ardekani B, Durand G, Le Calvez-Kelm F, Robinot N, Blanche H, Prokhortchouk E, Skryabin KG, Burdett L, Yeager M, Radojevic-Skodric S, Savic S, Foretova L, Holcatova I, Janout V, Mates D, Rascu S, Mukeria A, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Swiatkowska B, Benhamou S, Cancel-Tassin G, Cussenot O, Trichopoulou A, Riboli E, Overvad K, Panico S, Ljungberg B, Sitaram RT, Giles GG, Milne RL, Severi G, Bruinsma F, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Beane Freeman LE, Koutros S, Albanes D, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Chow WH, Moore LE, Choueiri TK, Wood C, Johansson M, McKay JD, Brown KM, Rothman N, Lathrop MG, Deleuze JF, Wu X, Brennan P, Chanock SJ, Purdue MP, Scelo G. Sex specific associations in genome wide association analysis of renal cell carcinoma. Eur J Hum Genet. 2019 10; 27(10):1589-1598.
    View in: PubMed
    Score: 0.010
  80. Clark PE, Streem SB, Geisinger MA. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol. 1999 Mar; 161(3):772-5; discussion 775-6.
    View in: PubMed
    Score: 0.010
  81. Ritch CR, Cookson MS, Clark PE, Chang SS, Fakhoury K, Ralls V, Thu MH, Penson DF, Smith JA, Silver HJ. Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial. J Urol. 2019 03; 201(3):470-477.
    View in: PubMed
    Score: 0.010
  82. Burgess EF, Livasy C, Hartman A, Robinson MM, Symanowski J, Naso C, Doherty S, Guerrieri R, Riggs S, Grigg CM, Clark PE, Raghavan D. Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. Urol Oncol. 2019 05; 37(5):299.e19-299.e25.
    View in: PubMed
    Score: 0.010
  83. Johansson M, Carreras-Torres R, Scelo G, Purdue MP, Mariosa D, Muller DC, Timpson NJ, Haycock PC, Brown KM, Wang Z, Ye Y, Hofmann JN, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Garnier JG, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Radojevic-Skodric S, Ognjanovic S, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Benhamou S, Cancel-Tassin G, Cussenot O, Weiderpass E, Ljungberg B, Tumkur Sitaram R, Häggström C, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Andreotti G, Beane Freeman LE, Koutros S, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Wilson KM, Gaziano JM, Sesso HD, Freedman ND, Parker AS, Eckel-Passow JE, Huang WY, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, Choueiri TK, Lathrop GM, Deleuze JF, Gunter M, McKay JD, Wu X, Houlston RS, Chanock SJ, Relton C, Richards JB, Martin RM, Davey Smith G, Brennan P. The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. PLoS Med. 2019 01; 16(1):e1002724.
    View in: PubMed
    Score: 0.009
  84. Copelan OR, Sanikommu SR, Trivedi JS, Butler C, Ai J, Ragon BK, Jacobs R, Knight TG, Usmani SZ, Grunwald MR, Ghosh N, Symanowski JT, Shahid Z, Clark PE, He J. Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor Transplantation. Biol Blood Marrow Transplant. 2019 04; 25(4):785-790.
    View in: PubMed
    Score: 0.009
  85. Fernández MI, Brausi M, Clark PE, Cookson MS, Grossman HB, Khochikar M, Kiemeney LA, Malavaud B, Sanchez-Salas R, Soloway MS, Svatek RS, Vikram R, Vrieling A, Kamat AM. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol. 2019 Jan; 37(1):3-13.
    View in: PubMed
    Score: 0.009
  86. David SN, Arnold Egloff SA, Goyal R, Clark PE, Phillips S, Gellert LL, Hameed O, Giannico GA. MAGI2 is an independent predictor of biochemical recurrence in prostate cancer. Prostate. 2018 06; 78(8):616-622.
    View in: PubMed
    Score: 0.009
  87. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 10; 15(10):1240-1267.
    View in: PubMed
    Score: 0.009
  88. Machiela MJ, Hofmann JN, Carreras-Torres R, Brown KM, Johansson M, Wang Z, Foll M, Li P, Rothman N, Savage SA, Gaborieau V, McKay JD, Ye Y, Henrion M, Bruinsma F, Jordan S, Severi G, Hveem K, Vatten LJ, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Freeman LEB, Koutros S, Albanes D, Mannisto S, Weinstein S, Clark PE, Edwards TE, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Gaziano JM, Sesso HS, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Colli LM, Sampson JN, Besse C, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Mijuskovic M, Ognjanovic M, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Szeszenia-Dabrowska N, Benhamou S, Cancel-Tassin G, Cussenot O, Bueno-de-Mesquita HB, Canzian F, Duell EJ, Ljungberg B, Sitaram RT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Wood C, Eisen T, Larkin J, Choueiri TK, Lathrop GM, Teh BT, Deleuze JF, Wu X, Houlston RS, Brennan P, Chanock SJ, Scelo G, Purdue MP. Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. Eur Urol. 2017 11; 72(5):747-754.
    View in: PubMed
    Score: 0.009
  89. Conti DV, Wang K, Sheng X, Bensen JT, Hazelett DJ, Cook MB, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Stevens VL, Berndt SI, Huff CD, Wang Z, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Stern MC, Jarai ZK, Govindasami K, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann T, Drake BF, Hu JJ, Clark PE, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJM, Han Y, Lubwama A, Thompson IM, Leach R, Easton DF, Schumacher F, Van den Berg DJ, Gundell SM, Stram A, Wan P, Xia L, Pooler LC, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Srivastava S, Eeles RA, Carpten J, Kibel AS, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Klein EA, Brureau L, Stram DO, Watya S, Chanock SJ, Witte JS, Blot WJ, Henderson BE, Haiman CA. Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. J Natl Cancer Inst. 2017 08 01; 109(8).
    View in: PubMed
    Score: 0.009
  90. Scelo G, Purdue MP, Brown KM, Johansson M, Wang Z, Eckel-Passow JE, Ye Y, Hofmann JN, Choi J, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Sampson JN, Abedi-Ardekani B, Besse C, Blanche H, Boland A, Burdette L, Chabrier A, Durand G, Le Calvez-Kelm F, Prokhortchouk E, Robinot N, Skryabin KG, Wozniak MB, Yeager M, Basta-Jovanovic G, Dzamic Z, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Szeszenia-Dabrowska N, Benhamou S, Cancel-Tassin G, Cussenot O, Baglietto L, Boeing H, Khaw KT, Weiderpass E, Ljungberg B, Sitaram RT, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Freeman LEB, Koutros S, Albanes D, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Wood C, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, Choueiri TK, Mark Lathrop G, Rothman N, Deleuze JF, McKay JD, Parker AS, Wu X, Houlston RS, Brennan P, Chanock SJ. Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nat Commun. 2017 06 09; 8:15724.
    View in: PubMed
    Score: 0.009
  91. Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, Clark PE, Davis BJ, Derweesh IH, Giambarresi L, Gervais DA, Hu SL, Lane BR, Leibovich BC, Pierorazio PM. Renal Mass and Localized Renal Cancer: AUA Guideline. J Urol. 2017 09; 198(3):520-529.
    View in: PubMed
    Score: 0.008
  92. Cate F, Kapp ME, Arnold SA, Gellert LL, Hameed O, Clark PE, Wile G, Coogan A, Giannico GA. Core Needle Biopsy and Fine Needle Aspiration Alone or in Combination: Diagnostic Accuracy and Impact on Management of Renal Masses. J Urol. 2017 06; 197(6):1396-1402.
    View in: PubMed
    Score: 0.008
  93. Arnold Egloff SA, Du L, Loomans HA, Starchenko A, Su PF, Ketova T, Knoll PB, Wang J, Haddad AQ, Fadare O, Cates JM, Lotan Y, Shyr Y, Clark PE, Zijlstra A. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. Oncotarget. 2017 Jan 03; 8(1):722-741.
    View in: PubMed
    Score: 0.008
  94. Yamashita H, Amponsa VO, Warrick JI, Zheng Z, Clark PE, Raman JD, Wu XR, Mendelsohn C, DeGraff DJ. On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. Nat Rev Urol. 2017 Feb; 14(2):98-106.
    View in: PubMed
    Score: 0.008
  95. Scarpato KR, Kappa SF, Goggins KM, Chang SS, Smith JA, Clark PE, Penson DF, Resnick MJ, Barocas DA, Idrees K, Kripalani S, Moses KA. The Impact of Health Literacy on Surgical Outcomes Following Radical Cystectomy. J Health Commun. 2016; 21(sup2):99-104.
    View in: PubMed
    Score: 0.008
  96. Goldstein J, Goyal R, Roland JT, Gellert LL, Clark PE, Hameed O, Giannico GA. MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma: ?A Comparison With AMACR. Am J Clin Pathol. 2016 Sep; 146(3):294-302.
    View in: PubMed
    Score: 0.008
  97. Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clark PE, Plimack ER. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol. 2016 09 20; 34(27):3346-8.
    View in: PubMed
    Score: 0.008
  98. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016 Oct; 196(4):1021-9.
    View in: PubMed
    Score: 0.008
  99. Austin DC, Strand DW, Love HL, Franco OE, Grabowska MM, Miller NL, Hameed O, Clark PE, Matusik RJ, Jin RJ, Hayward SW. NF-?B and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Prostate. 2016 08; 76(11):1004-18.
    View in: PubMed
    Score: 0.008
  100. Gregg JR, Emeruwa C, Wong J, Barocas DA, Chang SS, Clark PE, Cookson MS, Penson DF, Resnick MJ, Scarpato KR, Smith JA, Moses KA. Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. J Urol. 2016 Oct; 196(4):1030-5.
    View in: PubMed
    Score: 0.008
  101. Richmond BW, Brucker RM, Han W, Du RH, Zhang Y, Cheng DS, Gleaves L, Abdolrasulnia R, Polosukhina D, Clark PE, Bordenstein SR, Blackwell TS, Polosukhin VV. Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency. Nat Commun. 2016 Apr 05; 7:11240.
    View in: PubMed
    Score: 0.008
  102. Gregg JR, McCormick B, Wang L, Cohen P, Sun D, Penson DF, Smith JA, Clark PE, Cookson MS, Barocas DA, Resnick MJ, Moses KA, Chang SS. Short term complications from transurethral resection of bladder tumor. Can J Urol. 2016 Apr; 23(2):8198-203.
    View in: PubMed
    Score: 0.008
  103. Goldstein J, Borowsky AD, Goyal R, Roland JT, Arnold SA, Gellert LL, Clark PE, Hameed O, Giannico GA. MAGI-2 in prostate cancer: an immunohistochemical study. Hum Pathol. 2016 06; 52:83-91.
    View in: PubMed
    Score: 0.008
  104. Azawi NH, Joergensen SM, Jensen NV, Clark PE, Lund L. Trends in kidney cancer among the elderly in Denmark, 1980-2012. Acta Oncol. 2016; 55 Suppl 1:79-84.
    View in: PubMed
    Score: 0.008
  105. Austin DC, Strand DW, Love HL, Franco OE, Jang A, Grabowska MM, Miller NL, Hameed O, Clark PE, Fowke JH, Matusik RJ, Jin RJ, Hayward SW. NF-?B and androgen receptor variant expression correlate with human BPH progression. Prostate. 2016 Apr; 76(5):491-511.
    View in: PubMed
    Score: 0.008
  106. Grabowska MM, Kelly SM, Reese AL, Cates JM, Case TC, Zhang J, DeGraff DJ, Strand DW, Miller NL, Clark PE, Hayward SW, Gronostajski RM, Anderson PD, Matusik RJ. Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia. Endocrinology. 2016 Mar; 157(3):1094-109.
    View in: PubMed
    Score: 0.008
  107. Arnold SA, Loomans HA, Ketova T, Andl CD, Clark PE, Zijlstra A. Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. Clin Exp Metastasis. 2016 Jan; 33(1):29-44.
    View in: PubMed
    Score: 0.008
  108. Lovvorn HN, Pierce J, Libes J, Li B, Wei Q, Correa H, Gouffon J, Clark PE, Axt JR, Hansen E, Newton M, O'Neill JA. Genetic and chromosomal alterations in Kenyan Wilms Tumor. Genes Chromosomes Cancer. 2015 Nov; 54(11):702-15.
    View in: PubMed
    Score: 0.008
  109. Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA, Smith JA, Chang SS, Cookson MS, You C, Barocas DA, Grabowska MM, Ye F, Wu XR, Yi Y, Matusik RJ, Kaestner KH, Clark PE, DeGraff DJ. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. Am J Pathol. 2015 May; 185(5):1385-95.
    View in: PubMed
    Score: 0.007
  110. Corcoran AT, Kaffenberger SD, Clark PE, Walton J, Handorf E, Piotrowski Z, Tomaszewski JJ, Ginzburg S, Mehrazin R, Plimack E, Chen DY, Smaldone MC, Uzzo RG, Morgan TM, Kutikov A. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU Int. 2015 Sep; 116(3):351-7.
    View in: PubMed
    Score: 0.007
  111. Tang DH, Clark PE, Giannico G, Hameed O, Chang SS, Gellert LL. Lack of P16ink4a over expression in penile squamous cell carcinoma is associated with recurrence after lymph node dissection. J Urol. 2015 Feb; 193(2):519-25.
    View in: PubMed
    Score: 0.007
  112. Ritch CR, Cookson MS, Chang SS, Clark PE, Resnick MJ, Penson DF, Smith JA, May AT, Anderson CB, You C, Lee H, Barocas DA. Impact of complications and hospital-free days on health related quality of life 1 year after radical cystectomy. J Urol. 2014 Nov; 192(5):1360-4.
    View in: PubMed
    Score: 0.007
  113. Ritch CR, You C, May AT, Herrell SD, Clark PE, Penson DF, Chang SS, Cookson MS, Smith JA, Barocas DA. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology. 2014 Jun; 83(6):1309-15.
    View in: PubMed
    Score: 0.007
  114. Ark JT, Keegan KA, Barocas DA, Morgan TM, Resnick MJ, You C, Cookson MS, Penson DF, Davis R, Clark PE, Smith JA, Chang SS. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int. 2014 Jun; 113(6):894-9.
    View in: PubMed
    Score: 0.007
  115. Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA, Matusik RJ. NF-?B gene signature predicts prostate cancer progression. Cancer Res. 2014 May 15; 74(10):2763-72.
    View in: PubMed
    Score: 0.007
  116. Lin-Tsai O, Clark PE, Miller NL, Fowke JH, Hameed O, Hayward SW, Strand DW. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Prostate. 2014 May; 74(6):669-79.
    View in: PubMed
    Score: 0.007
  117. Thompson IM, Kappa SF, Morgan TM, Barocas DA, Bischoff CJ, Keegan KA, Stratton KL, Clark PE, Resnick MJ, Smith JA, Cookson MS, Chang SS. Blood loss associated with radical cystectomy: a prospective, randomized study comparing Impact LigaSure vs. stapling device. Urol Oncol. 2014 Jan; 32(1):45.e11-5.
    View in: PubMed
    Score: 0.007
  118. Spiess PE, Horenblas S, Pagliaro LC, Biagioli MC, Crook J, Clark PE, Greenberg RE, Ercole CE. Current concepts in penile cancer. J Natl Compr Canc Netw. 2013 May 01; 11(5):617-24.
    View in: PubMed
    Score: 0.006
  119. Ritch CR, Clark PE, Morgan TM. Restaging transurethral resection for non-muscle invasive bladder cancer: who, why, when, and how? Urol Clin North Am. 2013 May; 40(2):295-304.
    View in: PubMed
    Score: 0.006
  120. Davies JD, Simons CM, Ruhotina N, Barocas DA, Clark PE, Morgan TM. Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study. Urology. 2013 Feb; 81(2):358-63.
    View in: PubMed
    Score: 0.006
  121. Anderson CB, Morgan TM, Kappa S, Moore D, Clark PE, Davis R, Penson DF, Barocas DA, Smith JA, Cookson MS, Chang SS. Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol. 2013 Feb; 189(2):541-7.
    View in: PubMed
    Score: 0.006
  122. Morgan TM, Barocas DA, Keegan KA, Cookson MS, Chang SS, Ni S, Clark PE, Smith JA, Penson DF. Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol. 2012 Dec; 188(6):2139-44.
    View in: PubMed
    Score: 0.006
  123. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol. 2013 Jan; 63(1):4-15.
    View in: PubMed
    Score: 0.006
  124. Kaffenberger SD, Keegan KA, Bansal NK, Morgan TM, Tang DH, Barocas DA, Penson DF, Davis R, Clark PE, Chang SS, Cookson MS, Herrell SD, Smith JA. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J Urol. 2013 Feb; 189(2):507-13.
    View in: PubMed
    Score: 0.006
  125. Morgan TM, Barocas DA, Penson DF, Chang SS, Ni S, Clark PE, Smith JA, Cookson MS. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology. 2012 Sep; 80(3):632-40.
    View in: PubMed
    Score: 0.006
  126. Anderson CB, Cookson MS, Chang SS, Clark PE, Smith JA, Kaufman MR. Voiding function in women with orthotopic neobladder urinary diversion. J Urol. 2012 Jul; 188(1):200-4.
    View in: PubMed
    Score: 0.006
  127. DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 2012; 7(5):e36669.
    View in: PubMed
    Score: 0.006
  128. Anderson CB, Kaufman MR, Dietrich MS, Barocas DA, Chang SS, Cookson MS, Smith JA, Clark PE, Herrell SD. Recovery of urinary function after radical prostatectomy: identification of trajectory cluster groups. J Urol. 2012 Apr; 187(4):1346-51.
    View in: PubMed
    Score: 0.006
  129. Patel SG, Penson DF, Pabla B, Clark PE, Cookson MS, Chang SS, Herrell SD, Smith JA, Barocas DA. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol. 2012 Mar; 187(3):816-21.
    View in: PubMed
    Score: 0.006
  130. Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, Shariat SF, Svatek RS, Taylor JM. Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol. 2013 Aug; 31(6):812-26.
    View in: PubMed
    Score: 0.006
  131. Davies JD, Aghazadeh MA, Phillips S, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Penson DF, Smith JA, Barocas DA. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol. 2011 Dec; 186(6):2221-7.
    View in: PubMed
    Score: 0.006
  132. Broughton GJ, Clark PE, Barocas DA, Cookson MS, Smith JA, Herrell SD, Chang SS. Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively. BJU Int. 2012 Jun; 109(11):1607-13.
    View in: PubMed
    Score: 0.006
  133. DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. Urol Oncol. 2013 Aug; 31(6):802-11.
    View in: PubMed
    Score: 0.006
  134. Morgan TM, Barocas DA, Chang SS, Phillips SE, Salem S, Clark PE, Penson DF, Smith JA, Cookson MS. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol. 2013 Aug; 31(6):871-7.
    View in: PubMed
    Score: 0.006
  135. Stabler S, Koyama T, Zhao Z, Martinez-Ferrer M, Allen RH, Luka Z, Loukachevitch LV, Clark PE, Wagner C, Bhowmick NA. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One. 2011; 6(8):e22486.
    View in: PubMed
    Score: 0.006
  136. Morgan TM, Keegan KA, Barocas DA, Ruhotina N, Phillips SE, Chang SS, Penson DF, Clark PE, Smith JA, Cookson MS. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol. 2011 Sep; 186(3):829-34.
    View in: PubMed
    Score: 0.006
  137. Mitchell RE, Clark PE, Scarpero HM. Assessing the surgical skills of urology residents after preurology general surgery training: the surgical skills learning needs of new urology residents. J Surg Educ. 2011 Sep-Oct; 68(5):341-6.
    View in: PubMed
    Score: 0.006
  138. Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW. PPAR?: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation. 2011 Nov-Dec; 82(4-5):220-36.
    View in: PubMed
    Score: 0.006
  139. Anderson CB, Clark PE, Morgan TM, Stratton KL, Herrell SD, Davis R, Cookson MS, Smith JA, Chang SS. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology. 2011 Jul; 78(1):99-104.
    View in: PubMed
    Score: 0.006
  140. Thompson IM, Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. World J Urol. 2011 Feb; 29(1):15-20.
    View in: PubMed
    Score: 0.005
  141. Aghazadeh MA, Barocas DA, Salem S, Clark PE, Cookson MS, Davis R, Gregg J, Stimson CJ, Smith JA, Chang SS. Determining factors for hospital discharge status after radical cystectomy in a large contemporary cohort. J Urol. 2011 Jan; 185(1):85-9.
    View in: PubMed
    Score: 0.005
  142. Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R, Stimson CJ, Aghazadeh M, Smith JA, Barocas DA. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol. 2011 Jan; 185(1):90-6.
    View in: PubMed
    Score: 0.005
  143. Kijvikai K, Viprakasit DP, Milhoua P, Clark PE, Herrell SD. A simple, effective method to create laparoscopic renal protective hypothermia with cold saline surface irrigation: clinical application and assessment. J Urol. 2010 Nov; 184(5):1861-6.
    View in: PubMed
    Score: 0.005
  144. Newton MR, Phillips S, Chang SS, Clark PE, Cookson MS, Davis R, Fowke JH, Herrell SD, Baumgartner R, Chan R, Mishra V, Blume JD, Smith JA, Barocas DA. Smaller prostate size predicts high grade prostate cancer at final pathology. J Urol. 2010 Sep; 184(3):930-7.
    View in: PubMed
    Score: 0.005
  145. Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Wills ML, Shappell SB, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA. Comparative analysis of whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. J Urol. 2010 Oct; 184(4):1334-40.
    View in: PubMed
    Score: 0.005
  146. Stimson CJ, Chang SS, Barocas DA, Humphrey JE, Patel SG, Clark PE, Smith JA, Cookson MS. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010 Oct; 184(4):1296-300.
    View in: PubMed
    Score: 0.005
  147. Stimson CJ, Cookson MS, Barocas DA, Clark PE, Humphrey JE, Patel SG, Smith JA, Chang SS. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol. 2010 May; 183(5):1732-7.
    View in: PubMed
    Score: 0.005
  148. Koski ME, Makari JH, Adams MC, Thomas JC, Clark PE, Pope JC, Brock JW. Infant communicating hydroceles--do they need immediate repair or might some clinically resolve? J Pediatr Surg. 2010 Mar; 45(3):590-3.
    View in: PubMed
    Score: 0.005
  149. Kordan Y, Barocas DA, Altamar HO, Clark PE, Chang SS, Davis R, Herrell SD, Baumgartner R, Mishra V, Chan RC, Smith JA, Cookson MS. Comparison of transfusion requirements between open and robotic-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Oct; 106(7):1036-40.
    View in: PubMed
    Score: 0.005
  150. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010 May-Jun; 60(3):194-201.
    View in: PubMed
    Score: 0.005
  151. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010 Feb 16; 121(6):833-40.
    View in: PubMed
    Score: 0.005
  152. Barocas DA, Salem S, Kordan Y, Herrell SD, Chang SS, Clark PE, Davis R, Baumgartner R, Phillips S, Cookson MS, Smith JA. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. J Urol. 2010 Mar; 183(3):990-6.
    View in: PubMed
    Score: 0.005
  153. Kordan Y, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA, Barocas DA. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol. 2009 Dec; 182(6):2695-701.
    View in: PubMed
    Score: 0.005
  154. Stec AA, Stratton KL, Kaufman MR, Chang SS, Milam DF, Herrell SD, Dmochowski RR, Smith JA, Clark PE, Cookson MS. Open renal biopsy: comorbidities and complications in a contemporary series. BJU Int. 2010 Jul; 106(1):102-6.
    View in: PubMed
    Score: 0.005
  155. Lowrance WT, Rumohr JA, Clark PE, Chang SS, Smith JA, Cookson MS. Urinary diversion trends at a high volume, single American tertiary care center. J Urol. 2009 Nov; 182(5):2369-74.
    View in: PubMed
    Score: 0.005
  156. Kordan Y, Chang SS, Salem S, Cookson MS, Clark PE, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA, Barocas DA. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. J Urol. 2009 Nov; 182(5):2291-5.
    View in: PubMed
    Score: 0.005
  157. Mitchell RE, Lee BT, Cookson MS, Barocas DA, Herrell SD, Clark PE, Smith JA, Chang SS. Immediate surgical outcomes for radical prostatectomy in the University HealthSystem Consortium Clinical Data Base: the impact of hospital case volume, hospital size and geographical region on 48,000 patients. BJU Int. 2009 Nov; 104(10):1442-5.
    View in: PubMed
    Score: 0.005
  158. Mitchell RE, Lee BT, Cookson MS, Barocas DA, Duke Herrell S, Clark PE, Smith JA, Chang SS. Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base: Impact of hospital case volume, hospital size, and geographic location on 40,000 patients. Cancer. 2009 Jun 01; 115(11):2447-52.
    View in: PubMed
    Score: 0.005
  159. Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO, Clark PE, Hu JJ, Ochoa AC. Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis. 2009 Aug; 30(8):1358-62.
    View in: PubMed
    Score: 0.005
  160. Barocas DA, Patel SG, Chang SS, Clark PE, Smith JA, Cookson MS. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009 Oct; 104(8):1091-7.
    View in: PubMed
    Score: 0.005
  161. Patel SG, Cookson MS, Barocas DA, Clark PE, Smith JA, Chang SS. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int. 2009 Oct; 104(7):934-7.
    View in: PubMed
    Score: 0.005
  162. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. J Natl Compr Canc Netw. 2009 Jan; 7(1):8-39.
    View in: PubMed
    Score: 0.005
  163. Lewis JE, Soler-Vilá H, Clark PE, Kresty LA, Allen GO, Hu JJ. Intake of plant foods and associated nutrients in prostate cancer risk. Nutr Cancer. 2009; 61(2):216-24.
    View in: PubMed
    Score: 0.005
  164. Winterich JA, Grzywacz JG, Quandt SA, Clark PE, Miller DP, Acuña J, Dignan MB, Arcury TA. Men's knowledge and beliefs about prostate cancer: education, race, and screening status. Ethn Dis. 2009; 19(2):199-203.
    View in: PubMed
    Score: 0.005
  165. Boudreaux KJ, Clark PE, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Chang SS. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol. 2009 Feb; 181(2):540-5; discussion 546.
    View in: PubMed
    Score: 0.005
  166. Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA, Clark PE, Bhowmick NA. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res. 2008 Dec 01; 14(23):7790-7.
    View in: PubMed
    Score: 0.005
  167. Rossi PJ, Urbanic J, Clark PE, McCullough DL, Lee WR. Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. Brachytherapy. 2008 Oct-Dec; 7(4):286-9.
    View in: PubMed
    Score: 0.005
  168. Winterich JA, Quandt SA, Grzywacz JG, Clark PE, Miller DP, Acuña J, Arcury TA. Masculinity and the body: how African American and White men experience cancer screening exams involving the rectum. Am J Mens Health. 2009 Dec; 3(4):300-9.
    View in: PubMed
    Score: 0.005
  169. Chan RC, Barocas DA, Chang SS, Herrell SD, Clark PE, Baumgartner R, Smith JA, Cookson MS. Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy. BJU Int. 2008 May; 101(9):1140-4.
    View in: PubMed
    Score: 0.005
  170. Coons BJ, Clark PE, Maynes LJ, Terhune KP, Stokes MC, Beech DJ. Sigmoid-urachal-cutaneous fistula in an adult male. Urology. 2009 Feb; 73(2):444.e5-7.
    View in: PubMed
    Score: 0.005
  171. Lowrance WT, Rumohr JA, Chang SS, Clark PE, Smith JA, Cookson MS. Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol. 2008 Apr; 179(4):1313-8; discussion 1318.
    View in: PubMed
    Score: 0.004
  172. Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor OA, Hu JJ, Ochoa AC. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis. 2008 Mar; 29(3):573-8.
    View in: PubMed
    Score: 0.004
  173. Smith JA, Chan RC, Chang SS, Herrell SD, Clark PE, Baumgartner R, Cookson MS. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol. 2007 Dec; 178(6):2385-9; discussion 2389-90.
    View in: PubMed
    Score: 0.004
  174. Patel SG, Cookson MS, Clark PE, Smith JA, Chang SS. Neovesical-urethral anastomotic stricture after orthotopic urinary diversion: presentation and management. BJU Int. 2008 Jan; 101(2):219-22.
    View in: PubMed
    Score: 0.004
  175. Barbieri CE, Lee B, Cookson MS, Bingham J, Clark PE, Smith JA, Chang SS. Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol. 2007 Oct; 178(4 Pt 1):1418-21; discussion 1421-2.
    View in: PubMed
    Score: 0.004
  176. Bin L, Thorburn J, Thomas LR, Clark PE, Humphreys R, Thorburn A. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J Biol Chem. 2007 Sep 21; 282(38):28189-94.
    View in: PubMed
    Score: 0.004
  177. Yacoub J, Richardson C, Farmer M, Lee WR, Clark PE, Hurt G, Levine EA. Male breast cancer during treatment with leuprolide for prostate cancer. Clin Adv Hematol Oncol. 2007 Jul; 5(7):555-6; discussion 556-7.
    View in: PubMed
    Score: 0.004
  178. Lowrance WT, Cookson MS, Clark PE, Smith JA, Chang SS. Assessing retroperitoneal lymphadenectomy experience in United States urological residency programs. J Urol. 2007 Aug; 178(2):500-3; discussion 503.
    View in: PubMed
    Score: 0.004
  179. Papagikos MA, Rossi PJ, Urbanic JJ, deGuzman AF, McCullough DL, Clark PE, Lee WR. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. Am J Clin Oncol. 2007 Apr; 30(2):199-204.
    View in: PubMed
    Score: 0.004
  180. Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, M Mohler R, Torti FM. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Cancer. 2006 Sep 1; 107(5):1093-100.
    View in: PubMed
    Score: 0.004
  181. Rackley JD, Clark PE, Hall MC. Complementary and alternative medicine for advanced prostate cancer. Urol Clin North Am. 2006 May; 33(2):237-46, viii.
    View in: PubMed
    Score: 0.004
  182. Rossi PJ, Clark PE, Papagikos MA, McCullough DL, Lee WR. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urology. 2006 Feb; 67(2):349-53.
    View in: PubMed
    Score: 0.004
  183. Lockett KL, Hall MC, Clark PE, Chuang SC, Robinson B, Lin HY, Su LJ, Hu JJ. DNA damage levels in prostate cancer cases and controls. Carcinogenesis. 2006 Jun; 27(6):1187-93.
    View in: PubMed
    Score: 0.004
  184. Gwynn ES, Clark PE, Hall MC. Recent advances in the treatment of bladder cancer. Expert Rev Anticancer Ther. 2005 Dec; 5(6):1023-30.
    View in: PubMed
    Score: 0.004
  185. Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2005 May; 17(3):275-80.
    View in: PubMed
    Score: 0.004
  186. Papagikos MA, Deguzman AF, Rossi PJ, McCullough DL, Clark PE, Lee WR. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? Brachytherapy. 2005; 4(4):252-8.
    View in: PubMed
    Score: 0.004
  187. Lockett KL, Hall MC, Xu J, Zheng SL, Berwick M, Chuang SC, Clark PE, Cramer SD, Lohman K, Hu JJ. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res. 2004 Sep 01; 64(17):6344-8.
    View in: PubMed
    Score: 0.004
  188. Zagoria RJ, Hawkins AD, Clark PE, Hall MC, Matlaga BR, Dyer RB, Chen MY. Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success. AJR Am J Roentgenol. 2004 Jul; 183(1):201-7.
    View in: PubMed
    Score: 0.003
  189. Kubinski DJ, Clark PE, Assimos DG, Hall MC. Utility of frozen section analysis of resection margins during partial nephrectomy. Urology. 2004 Jul; 64(1):31-4.
    View in: PubMed
    Score: 0.003
  190. Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2004 May; 16(3):257-62.
    View in: PubMed
    Score: 0.003
  191. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, Skinner DG. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):640-5.
    View in: PubMed
    Score: 0.003
  192. Matlaga BR, Zagoria RJ, Clark PE, Hall MC. Radiofrequency ablation of renal tumors. Curr Urol Rep. 2004 Feb; 5(1):39-44.
    View in: PubMed
    Score: 0.003
  193. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 01; 98(5):955-61.
    View in: PubMed
    Score: 0.003
  194. Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2003 May; 15(3):227-33.
    View in: PubMed
    Score: 0.003
  195. Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res. 2003 Mar; 1(5):385-92.
    View in: PubMed
    Score: 0.003
  196. Wilson SS, Clark PE, Stein JP. Angiomyolipoma with vena caval extension. Urology. 2002 Oct; 60(4):695-6.
    View in: PubMed
    Score: 0.003
  197. Uzzo RG, Rayman P, Kolenko V, Clark PE, Cathcart MK, Bloom T, Novick AC, Bukowski RM, Hamilton T, Finke JH. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J Clin Invest. 1999 Sep; 104(6):769-76.
    View in: PubMed
    Score: 0.002
  198. Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L, Tannenbaum C, Worford LJ, Bukowski R, Tubbs R, Hsi ED, Bander NH, Novick AC, Finke JH. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res. 1999 May; 5(5):1219-29.
    View in: PubMed
    Score: 0.002
  199. Uzzo RG, Clark PE, Rayman P, Bloom T, Rybicki L, Novick AC, Bukowski RM, Finke JH. Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst. 1999 Apr 21; 91(8):718-21.
    View in: PubMed
    Score: 0.002
  200. Capelouto CC, Clark PE, Ransil BJ, Loughlin KR. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol. 1995 Mar; 153(3 Pt 2):981-5.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.